Tumour Virology Lab receives 5-year grant from AIRC

The ICGEB Tumour Virology Laboratory has received a 5-year grant from the Associazione Italiana per la Ricerca sul Cancro AIRC.

The Laboratory focusses their attention on Human Papillomavirsues (HPVs) which are the causative agents of a large number of human malignancies, of which cervical cancer is by far the most important.

In many ICGEB Member Countries, cervical cancer is the major cause of cancer-related death, and despite the availability of very efficacious vaccines, there are still over 500,000 cases of cervical cancer annually. Thus the development of more effective and specific cancer therapeutics remains a pressing problem.

The ICGEB Tumour Virology Laboratory is a world leader in HPV research and this has been recently recognised in the award of over 500,000 euro from the AIRC to support the laboratory’s work on understanding how HPV causes cancer and in identifying new means for therapeutic intervention. The AIRC is a wonderful supporter of cancer research in Italy and ICGEB is proud to partner with them in helping to understand carcinogenesis and to develop new cancer therapies.   

The grant has been awarded for the characterisation of the functions of the Human Papillomavirus E6 and E7 Oncoproteins.

Om Basukala, PhD, Tumour Virology Lab, ICGEB Trieste